- Home
- ODD vs SVRA Comparison
ODD vs SVRA Comparison
Compare ODD & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | SVRA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 973.7M | 1.1B |
| IPO Year | 2022 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ODD | SVRA |
|---|---|---|
| Price | $17.56 | $4.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $16.94 | $11.06 |
| AVG Volume (30 Days) | 828.4K | ★ 2.8M |
| Earning Date | 11-11-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.75 | $9,266.31 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.25 | $4.13 |
| 52 Week High | $46.45 | $7.01 |
Technical Indicators
Market Signals| Indicator | ODD | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 46.80 |
| Support Level | $17.08 | $4.23 |
| Resistance Level | $17.68 | $5.47 |
| Average True Range (ATR) | 1.83 | 0.31 |
| MACD | -0.61 | 0.02 |
| Stochastic Oscillator | 17.24 | 40.91 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).